Angelman Syndrome Drug Pipeline — PatSnap Eureka
Angelman Syndrome Drug Pipeline: UBE3A Reactivation, ASO & Gene Replacement
No approved disease-modifying therapies exist for Angelman syndrome — a neurodevelopmental disorder affecting ~1 in 15,000 individuals. PatSnap Eureka maps the full patent and literature landscape across shRNA, ASO, AAV gene replacement, CRISPR, and small-molecule approaches targeting UBE3A restoration.
The UBE3A Imprinting Mechanism Driving Angelman Syndrome
Angelman syndrome (AS) is a severe neurodevelopmental disorder arising from loss of function of the maternal copy of UBE3A, encoding E3 ubiquitin-protein ligase E3A (also known as E6-AP). In neurons specifically, UBE3A is expressed exclusively from the maternal allele due to genomic imprinting: the paternal allele is silenced in cis by a long non-coding RNA antisense transcript designated UBE3A-ATS, embedded within the larger SNHG14 locus on chromosome 15q11-13.
The clinical phenotype encompasses developmental delay, severe cognitive impairment, ataxic gait, frequent seizures, absent speech, and a characteristic happy demeanor. Neurons derived from patient iPSCs exhibit depolarized resting membrane potential, delayed action potential development, and reduced spontaneous synaptic activity.
Three molecular targets dominate the retrieved patent landscape: UBE3A-ATS (the antisense suppressor lncRNA), SNORD115/SNHG14 (snoRNA loci within UBE3A-ATS), and the UBE3A protein/ORF itself — the direct replacement target for AAV-mediated gene therapy. PatSnap's life sciences intelligence platform tracks all three target classes across global filings.
F. Hoffmann-La Roche AG filings additionally identify UBE3A protein-level biomarkers as target engagement tools, noting that downstream protein substrates of UBE3A are modulated when UBE3A expression changes, providing pharmacodynamic readouts for drug development programs.
Six Intervention Strategies in the Angelman Syndrome Drug Pipeline
Patent filings from 2015–2026 reveal a diverse pipeline converging on UBE3A restoration through RNA silencing, gene delivery, genome editing, and small-molecule epigenetic approaches.
shRNA / Viral Vector–Mediated UBE3A-ATS Knockdown
The most extensively represented modality in the dataset, with at least 10 distinct patent filings from Ovid Therapeutics Inc. and the University of Connecticut. shRNAs target either UBE3A-ATS directly or SNORD115 loci within SNHG14, de-repressing the silenced paternal UBE3A allele in neurons. AAV-based ICV delivery is inferred from multiple filings. NIH Contract 1R01HD094953 is co-declared in all Ovid filings.
10+ Ovid Therapeutics filings · WO/US/CA/AU/IN/JP/KR/CNAntisense Oligonucleotides (ASOs) Targeting SNHG14 / UBE3A-ATS
F. Hoffmann-La Roche AG holds the most substantial ASO IP position, with multiple active EP, CA, and AU patents covering oligonucleotides that hybridize to the SNHG14 lncRNA downstream of SNORD109B to derepress paternal UBE3A. The divisional filing lineage extends to 2015 (EP 15194367/PCT/EP2016/077383), indicating one of the longest-running AS oligonucleotide IP positions in the dataset. The mechanism involves Watson-Crick base pairing blocking the antisense suppressor function in neurons.
Roche ASO lineage from 2015 · EP / CA / AU / CRAAV-Mediated UBE3A Gene Replacement
Direct neuronal delivery of functional UBE3A coding sequences via recombinant AAV vectors. Key details: AAV-PHP.B with neuronal promoter hSyn driving codon-optimized hUBE3A isoform 1 or isoforms 1 and 3. ICV delivery achieves 20–68% UBE3A-positive neurons across cortex, hippocampus, thalamus, hypothalamus, and midbrain at 10¹⁰–10¹¹ GC/animal. NHP studies show hUBE3A-1 distribution in dorsal root ganglia across cervical, thoracic, and lumbar segments over 35 days (n=3). Assignees include University of Pennsylvania, UC, UNC, and Ginkgo Bioworks.
Mouse & NHP preclinical data disclosed · 4+ assigneesCRISPR/Cas-Based UBE3A-ATS Unsilencing
Two distinct CRISPR modalities appear: Cas9-based editing — University of North Carolina discloses AAV9-delivered SaCas9 with guide RNA (Sajw33) targeting UBE3A-ATS, demonstrated to unsilence paternal Ube3a in mouse hippocampal and cortical neurons following P1 ICV injection. Cas13-based RNA cleavage — University of California discloses a Cas13 + guide RNA system targeting UBE3A-ATS RNA transcripts without disrupting SNORD116 or SNORD115 snoRNA expression, offering RNA-level precision without permanent genomic modification.
UNC (Cas9) · UC Regents (Cas13) · WO/CN filingsSmall Molecule Epigenetic Unsilencing
University of North Carolina at Chapel Hill discloses small molecules targeting chromatin regulatory enzymes to induce Ube3a expression in neurons. Targets include inhibitors of CDK5, DOT1L, EZH2, EHMT1/2, and ASH1L. Specific compounds include EPZ5676 (DOT1L inhibitor) and PHA533533 (CDK inhibitor) in combination regimens. Harvard Medical School separately discloses AMPAR potentiation as a symptomatic approach, based on evidence of reduced synaptic AMPAR activity in AS neurons.
CDK5 / DOT1L / EZH2 / EHMT1/2 targets · UNC 2022 US filingBiomarker & Pharmacodynamic Tools
Biogen MA Inc. discloses mass spectrometry–based methods for quantifying UBE3A protein in human samples (CSF or blood), enabling pharmacodynamic monitoring of therapeutic UBE3A restoration — a critical IND-enabling tool. F. Hoffmann-La Roche AG identifies downstream UBE3A substrate proteins as target engagement biomarkers. The PP2A/PTPA axis (Shanghai Institutes for Biological Sciences) identifies PTPA as a UBE3A ubiquitination substrate whose dysregulation contributes to AS and autism phenotypes.
Biogen mass spec UBE3A detection · Roche substrate biomarkersVisualising the Angelman Syndrome IP Landscape
Key quantitative signals from retrieved patent filings, illustrating assignee concentration, translational readiness, and modality coverage across the pipeline.
Patent Filings by Lead Assignee (AS-Specific)
Ovid Therapeutics dominates with 10+ filings; Roche holds the most mature ASO position with filings spanning 2015–2024.
AAV-UBE3A Neuronal Transduction by Brain Region (Mouse Model)
ICV delivery of AAV-UBE3A achieves 20–68% UBE3A-positive neurons across key brain regions at doses of 10¹⁰–10¹¹ GC/animal (University of Pennsylvania filings).
Key Patent Holders in the Angelman Syndrome Pipeline
Commercial biotech and academic organisations hold distinct IP positions across all three principal modalities. Freedom-to-operate analysis must span all simultaneously.
| Assignee | Modality | Key Jurisdictions | Filing Period | IP Notes |
|---|---|---|---|---|
| Ovid Therapeutics Inc. | shRNA/RNAi | WO, US, CA, AU, IN, JP, KR, CN | 2023–2025 | 10+ filings; NIH Contract 1R01HD094953 co-declared; global prosecution active |
| F. Hoffmann-La Roche AG | ASO | EP, CA, AU, CR | 2015–2024 | Longest-running AS oligonucleotide IP; divisional lineage from EP 15194367 |
| University of North Carolina | AAV CRISPR Small Mol. | WO, CA, CN, US | 2020–2022 | Broadest modality coverage; Bayh-Dole federal funding disclosures apply |
| Univ. of Pennsylvania | AAV | MX, JP | 2023 | Mouse & NHP preclinical data disclosed; hSyn promoter specificity |
| Univ. of California (Regents) | AAV Cas13 | WO, IL, AU, SG | 2021–2023 | Cas13 RNA cleavage preserves SNORD115/SNORD116; novel precision approach |
| Ginkgo Bioworks, Inc. | AAV | WO, US | 2024 | Recent entry; AAV expression cassettes for UBE3A gene replacement |
| Biogen MA Inc. | Biomarker | WO, US | 2021–2023 | Mass spec UBE3A protein detection; IND-enabling companion diagnostic IP |
| University of Connecticut | shRNA | WO, CA, US, AU | 2021–2025 | shRNA, ribozyme, and microRNA approaches; federal funding disclosed |
Need a freedom-to-operate assessment for UBE3A therapeutics?
PatSnap Eureka surfaces claim overlaps, prosecution history, and licensing signals across all AS patent families.
Strategic Implications for AS Drug Development
Key IP and translational signals that should inform asset acquisition, licensing strategy, and clinical program design in Angelman syndrome.
UBE3A-ATS Is the Single Most Important Target
All reactivation approaches — shRNA, ASO, Cas9, Cas13 — converge on disrupting this antisense suppressor. IP around this target is multilayered, with both RNA-targeting and DNA-editing strategies filed by distinct assignees. Entry requires freedom-to-operate analysis across all three modalities simultaneously.
AAV Gene Replacement Faces a Selectivity Ceiling
Retrieved data indicate that AAV-UBE3A delivery achieves partial neuronal transduction (20–68%), and NHP dorsal root ganglion distribution signals potential off-target tissue concerns requiring clinical monitoring. Promoter specificity (hSyn) is a partial mitigation. Patients with large maternal deletions may require this approach exclusively.
Biomarker Development Is a Strategic Gap
Biogen's UBE3A mass spectrometry detection IP and Roche's substrate biomarker portfolio represent critical enabling infrastructure for clinical trials. Organisations lacking biomarker strategies will face dose-selection and go/no-go decision challenges. This is a competitive differentiator for programs entering clinical stage.
Government Co-Invention Rights Are an IP Encumbrance
All Ovid Therapeutics shRNA filings carry NIH co-invention rights (Contract 1R01HD094953). Academic assignees (UNC, UConn, UC) similarly carry federal funding disclosures. IP strategists must account for Bayh-Dole march-in rights and government use licenses when evaluating asset acquisition or licensing.
Preclinical Evidence Base: What the Patent Record Reveals
Retrieved results do not contain explicit references to Phase I, Phase II, or Phase III clinical trial data, published clinical outcomes, or regulatory submissions for any AS therapeutic modality. The evidence base is entirely preclinical. Key translational signals present in retrieved patents include in vivo mouse model data, non-human primate studies, iPSC-derived neuron models, government funding disclosures, and biomarker development activities.
University of Pennsylvania filings describe ICV AAV delivery achieving 20–68% UBE3A-positive neurons in AS model mice (Ube3am−/p+) across cortex, hippocampus, thalamus, hypothalamus, and midbrain at doses of 10¹⁰–10¹¹ GC/animal. Non-human primate studies describe engineered hUBE3A-1 transcript distribution in NHP dorsal root ganglia (cervical, thoracic, and lumbar segments) across a 35-day study (n=3 NHPs).
Multiple filings reference AS patient iPSC-derived neurons showing depolarized resting membrane potential, delayed action potential development, and reduced spontaneous synaptic activity as disease-relevant endpoints for therapeutic evaluation. NIH Contract 1R01HD094953 cited in Ovid Therapeutics filings indicates active funded research consistent with IND-enabling stage activity.
Biogen MA Inc.'s mass spectrometry UBE3A protein detection methods constitute an IND-enabling tool for clinical monitoring. PatSnap's IP analytics tools can surface prosecution timelines and clinical linkage signals across all these programs. For broader life sciences pipeline context, see PatSnap's life sciences solutions.
Angelman Syndrome Drug Pipeline — Key Questions Answered
Angelman syndrome arises from loss of function of the maternal copy of UBE3A, encoding E3 ubiquitin-protein ligase E3A (also known as E6-AP). In neurons specifically, UBE3A is expressed exclusively from the maternal allele due to genomic imprinting: the paternal allele is silenced in cis by a long non-coding RNA antisense transcript designated UBE3A-ATS, which is itself embedded within the larger SNHG14 locus.
The disease prevalence is consistently cited across retrieved patents as approximately 1 in 15,000 individuals, with over 3,000 patients enrolled in dedicated registries and approximately 250 new diagnoses per year.
The field has converged on three principal intervention strategies: paternal UBE3A allele reactivation via RNA interference or oligonucleotide approaches, direct gene replacement using recombinant AAV vectors, and epigenetic/small-molecule unsilencing of the silenced paternal allele. CRISPR-based approaches using Cas9 and Cas13 are also represented in the patent landscape.
Ovid Therapeutics dominates shRNA/RNAi IP with at least 10 patent filings across WO, US, CA, AU, IN, JP, KR, and CN jurisdictions. F. Hoffmann-La Roche AG holds the most mature ASO position, with a divisional filing lineage extending to 2015. University of North Carolina, University of Pennsylvania, University of California, and Ginkgo Bioworks divide AAV gene replacement IP.
University of Pennsylvania filings describe ICV AAV delivery achieving 20–68% UBE3A-positive neurons in AS model mice across cortex, hippocampus, thalamus, hypothalamus, and midbrain at doses of 10^10–10^11 GC/animal. Non-human primate studies describe engineered hUBE3A-1 transcript distribution in NHP dorsal root ganglia across cervical, thoracic, and lumbar segments across a 35-day study (n=3 NHPs).
There are no approved disease-modifying therapies for Angelman syndrome. Retrieved results do not contain explicit references to Phase I, Phase II, or Phase III clinical trial data, published clinical outcomes, or regulatory submissions for any AS therapeutic modality. The evidence base in this dataset is entirely preclinical.
Still have questions about the Angelman syndrome patent landscape? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About AS PatentsAccelerate Your Angelman Syndrome R&D with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map UBE3A patent landscapes, identify white spaces, and de-risk drug development decisions.
References
- E3 Ubiquitin Ligase (UBE3A) Protein Targets — F. Hoffmann-La Roche AG (translated from Chinese filing), 2024, CN [Patent]
- Protein Targets of E3 Ubiquitin Ligase (UBE3A) — F. Hoffmann-La Roche AG (translated from Japanese filing), 2024, JP [Patent]
- Antisense Oligomers for Treatment of Autosomal Dominant Mental Retardation Type 5 and Dravet Syndrome — Cold Spring Harbor Laboratory (translated from Chinese filing), 2019, CN [Patent]
- Gapmer Antisense Oligonucleotides with Modified Backbone Chemistry — Quiris Inc. (translated from Chinese filing), 2025, CN [Patent]
- Modified UBE3A Gene for a Gene Therapy Approach for Angelman Syndrome — University of South Florida, 2023, EP [Patent]
- Methods and Compositions for Treatment of Angelman Syndrome (CRISPR/Cas9) — University of North Carolina at Chapel Hill (translated from Chinese filing), 2020, CN [Patent]
- Compositions and Methods for Treatment of Angelman Syndrome (Cas13) — The Regents of the University of California, 2023, WO [Patent]
- Methods and Compositions for Unsilencing Imprinted Genes — The University of North Carolina at Chapel Hill, 2022, US [Patent]
- Application of Ube3a Ubiquitination of PP2A Activator PTPA in Treating Angelman Syndrome and Autism — Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (translated from Chinese filing), 2019, CN [Patent]
- Methods and Compositions for Treatment of Angelman Syndrome and Autism Spectrum Disorders — President and Fellows of Harvard College, 2016, US [Patent]
- Methods of Detecting UBE3A Protein — Biogen MA Inc., 2023, US [Patent]
- Oligonucleotides for Inducing Paternal UBE3A Expression — F. Hoffmann-La Roche AG, 2024, EP [Patent]
- shRNA Targeting SNORD115 Locations to Restore Paternal UBE3A Gene Expression in Angelman Syndrome — Ovid Therapeutics Inc., 2023, WO [Patent]
- Methods and Compositions for Increasing Expression of UBE3A — Encoding Therapeutics (translated from Traditional Chinese filing), 2026, TW [Patent]
- UBE3A Genes and Expression Cassettes and Their Use — The University of North Carolina at Chapel Hill, 2020, WO [Patent]
- Compositions and Uses for Treating Angelman Syndrome (rAAV-UBE3A, gene editing) — The Trustees of the University of Pennsylvania (translated from Japanese filing), 2023, JP [Patent]
- Gene Therapy for Angelman Syndrome — Ginkgo Bioworks, Inc., 2024, US [Patent]
- Compositions and Methods to Restore Paternal UBE3A Gene Expression in Human Angelman Syndrome — University of Connecticut, 2025, AU [Patent]
- shRNA Targeting UBE3A-ATS to Restore Paternal UBE3A Gene Expression in Angelman Syndrome — Ovid Therapeutics Inc., 2023, US [Patent]
- Methods of Detecting UBE3A Protein — Biogen MA Inc., 2021, WO [Patent]
- National Institute of Neurological Disorders and Stroke (NINDS) — Angelman Syndrome Information
- National Center for Biotechnology Information (NCBI / PubMed) — UBE3A imprinting and iPSC neuron research
- Orphanet — Angelman Syndrome rare disease registry and epidemiology data
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent records are retrieved via PatSnap Eureka. This page represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches global patent filings and research literature to answer instantly.